DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Cyclophosphamide (Cyclophosphamide) - Neutropenia - Suspected Cause - Side Effect Reports

 
 



Index of reports > Cases with Neutropenia (401)

Below is the selection of side effect reports (a.k.a. adverse event reports) related to Cyclophosphamide where reactions include neutropenia. The selected reports were submitted to the FDA during the sample period of about a year.

 Reports 1 - 30 of 401   Next >>

Possible Cyclophosphamide side effects in

Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-27

Patient:

Reactions: Off Label Use, Gastrointestinal Toxicity, Neutropenia, Infection

Drug(s) suspected as cause:
Carboplatin
    Dosage: 6 courses in high risk
    Indication: Retinoblastoma

Cyclophosphamide
    Indication: Retinoblastoma

Doxorubicin Hydrochloride
    Dosage: 4 courses in intermediate risk and 6 courses in high risk
    Indication: Retinoblastoma

Etoposide
    Indication: Retinoblastoma

Vincristine
    Dosage: 4 courses in intermediate risk and 6 courses in high risk
    Indication: Retinoblastoma

Other drugs received by patient: Neupogen



Possible Cyclophosphamide side effects in male

Reported by a physician from Germany on 2012-08-24

Patient: male

Reactions: Febrile Neutropenia, Skin Infection, Neutropenia, Pneumonitis

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 1500 mg, unk
    Indication: B-Cell Lymphoma
    Start date: 2012-02-02
    End date: 2012-04-17

Doxorubicin Hydrochloride
    Dosage: 100 mg, unk
    Indication: B-Cell Lymphoma
    Start date: 2012-02-02
    End date: 2012-04-17

Neulasta
    Dosage: 6 mg, unk
    Indication: B-Cell Lymphoma
    Start date: 2012-02-06
    End date: 2012-04-20

Prednisolone
    Dosage: 100 mg, unk
    Administration route: Oral
    Indication: B-Cell Lymphoma
    Start date: 2012-02-02
    End date: 2012-04-21

Rituximab
    Dosage: 750 mg, unk
    Indication: B-Cell Lymphoma
    Start date: 2012-02-01
    End date: 2012-04-16

Vincristine
    Dosage: 2 mg, unk
    Indication: B-Cell Lymphoma
    Start date: 2012-02-02
    End date: 2012-04-17

Other drugs received by patient: MST / 00036302 /; Novalgin / 00169801 /; Rulid; Pantoprazole; Paspertin / 00041902 /; Acyclovir; Electrolytes NOS W / Macrogol 3350; Dipyrone INJ; Metoclopramide; Acyclovir



Possible Cyclophosphamide side effects in male

Reported by a physician from United States on 2012-08-24

Patient: male, weighing 26.9 kg (59.2 pounds)

Reactions: Tachycardia, Fungal Sepsis, Status Epilepticus, Oral Candidiasis, Hypomagnesaemia, Acute Respiratory Distress Syndrome, Bradycardia, Neutropenia, Blood Pressure Decreased, Shock

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
C-CSF (Filgrastim, Amgen)
    Dosage: 135 mg

Cisplatin
    Dosage: 74 mg

Cyclophosphamide
    Dosage: 1960 mg

Isotretinoin
    Dosage: 80 mg

Vincristine Sulfate
    Dosage: 2.8 mg



Possible Cyclophosphamide side effects in female

Reported by a physician from Thailand on 2012-08-24

Patient: female, weighing 57.4 kg (126.3 pounds)

Reactions: Neutropenia

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: B-Cell Lymphoma
    Start date: 2012-03-02

Doxorubicin Hydrochloride
    Indication: B-Cell Lymphoma
    Start date: 2012-03-02

Mabthera
    Indication: B-Cell Lymphoma
    Start date: 2012-03-02

Prednisone TAB
    Indication: B-Cell Lymphoma
    Start date: 2012-03-02

Vincristine
    Indication: B-Cell Lymphoma
    Start date: 2012-03-02

Other drugs received by patient: Dexamethasone; Acetaminophen; Ondansetron; Metformin HCL; Ondansetron; Ondansetron; Atenolol; Simvastatin; Benadryl



Possible Cyclophosphamide side effects in 65 year old female

Reported by a physician from Japan on 2012-08-24

Patient: 65 year old female, weighing 50.2 kg (110.6 pounds)

Reactions: Weight Decreased, Blood Bilirubin Increased, Cytomegalovirus Viraemia, Headache, Pyrexia, Interstitial Lung Disease, Oedema, Thrombocytopenia, Blood Sodium Decreased, Decreased Appetite, Vomiting, Stomatitis, Pneumonia, Alanine Aminotransferase Increased, Lymphopenia, Anaemia, Febrile Neutropenia, Rash, Blood Phosphorus Decreased, Blood Potassium Decreased, Diarrhoea, Alopecia, Aspartate Aminotransferase Increased, Neutropenia, Leukopenia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Adriamycin PFS
    Dosage: 30 mg/m2 x 1/4 week
    Start date: 2011-03-16

Adriamycin PFS
    Dosage: 40 mg/m2 x 1/4 week
    Indication: Adult T-Cell Lymphoma / Leukaemia
    Start date: 2011-03-09

Carboplatin
    Dosage: 250 mg/m2 x 1/4 week
    Indication: Adult T-Cell Lymphoma / Leukaemia
    Start date: 2011-03-24

Cyclophosphamide
    Dosage: 350 mg/m2 x 1/4 week
    Indication: Adult T-Cell Lymphoma / Leukaemia
    Start date: 2011-03-09

Etoposide
    Dosage: 100 mg/m2 x 1/4 week
    Indication: Adult T-Cell Lymphoma / Leukaemia
    Start date: 2011-03-24

Prednisolone
    Dosage: 40 mg/m2 x 1/4 week
    Administration route: Oral
    Indication: Adult T-Cell Lymphoma / Leukaemia
    Start date: 2011-03-09

Prednisolone
    Dosage: 1mg/kg x 1/2 week
    Start date: 2011-12-13
    End date: 2011-12-14

Prednisolone
    Dosage: 40 mg/m2 x 1/4 week
    Administration route: Oral
    Start date: 2011-03-16

Prednisolone
    Dosage: 2 mg/m2, 1x/day
    Administration route: Oral
    Start date: 2011-03-24

Ranimustine
    Dosage: 60 mg/m2 x 1/4 week
    Indication: Adult T-Cell Lymphoma / Leukaemia
    Start date: 2011-03-16

Vincristine Sulfate
    Dosage: 1 mg/m2 x 1/4 week
    Indication: Adult T-Cell Lymphoma / Leukaemia
    Start date: 2011-03-09

Vindesine Sulfate
    Dosage: 2.4 mg/m2 x 1/4 week
    Indication: Adult T-Cell Lymphoma / Leukaemia
    Start date: 2011-03-24

Other drugs received by patient: Mucosolvan; Lansoprazole; Sulfamethoxazole and Trimethoprim; Armodafinil; Zolpidem; Olopatadine HCL; Cefazolin Sodium; Ciprofloxacin HCL; Armodafinil; Zovirax; Magmitt; Alendronate Sodium



Possible Cyclophosphamide side effects in 52 year old female

Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-24

Patient: 52 year old female

Reactions: Tumour Lysis Syndrome, Posterior Reversible Encephalopathy Syndrome, Insomnia, Neutropenia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: according to larson regimen
    Indication: B Precursor Type Acute Leukaemia

Daunorubicin HCL
    Dosage: according to larson regimen
    Indication: B Precursor Type Acute Leukaemia

Daunorubicin HCL
    Dosage: at 50% dosage

Dexamethasone
    Indication: Premedication

Methylprednisolone Sodium Succinate
    Indication: B Precursor Type Acute Leukaemia

Prednisone TAB
    Dosage: according to larson regimen
    Indication: B Precursor Type Acute Leukaemia

Vincristine
    Dosage: according to larson regimen
    Indication: B Precursor Type Acute Leukaemia

Other drugs received by patient: Ondansetron; Voriconazole; Morphine Sulfate; Morphine



Possible Cyclophosphamide side effects in male

Reported by a individual with unspecified qualification from United States on 2012-08-23

Patient: male, weighing 26.9 kg (59.2 pounds)

Reactions: Abdominal Pain, Dyspnoea, Dilatation Ventricular, Tachycardia, Fungal Sepsis, Status Epilepticus, Pyrexia, Hemiparesis, Breath Sounds Abnormal, Hypophagia, Hypomagnesaemia, Acute Respiratory Distress Syndrome, Shunt Malfunction, Neutropenia, Blood Pressure Decreased, Shock

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cisplatin
    Dosage: 74 mg

Cyclophosphamide
    Dosage: 1960 mg

G-CSF (Filgrastim, Amgen)
    Dosage: 135 mg

Isotretinoin
    Dosage: 80 mg

Vincristine Sulfate
    Dosage: 2.8 mg



Possible Cyclophosphamide side effects in female

Reported by a individual with unspecified qualification from United States on 2012-08-23

Patient: female, weighing 81.8 kg (180.0 pounds)

Reactions: Dyspnoea, Chest Pain, Pancytopenia, Pyrexia, Neutropenia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 1400 mg

Doxorubicin Hydrochloride
    Dosage: 94 mg

Prednisone
    Dosage: 375 mg

Rituximab (Moab C2b8 Anti Cd20, Chimeric)
    Dosage: 700 mg

Vincristine Sulfate
    Dosage: 2 mg



Possible Cyclophosphamide side effects in male

Reported by a physician from United States on 2012-08-22

Patient: male, weighing 94.0 kg (206.8 pounds)

Reactions: Tachycardia, Clostridium Difficile Colitis, Pancytopenia, Neutropenia, Pyrexia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 2780 mg

Doxorubicin Hydrochloride
    Dosage: 152 mg

Etoposide
    Dosage: 720 mg

Fluorine-18 2-Fluorou-2 Deoxyry-D-Glucose (18f-Fdg)
    Dosage: 12 mg

Prednisone
    Dosage: 1300 mg

Rituximab
    Dosage: 800 mg

Vincristine Sulfate
    Dosage: 3.6 mg



Possible Cyclophosphamide side effects in

Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-21

Patient:

Reactions: Off Label Use, Gastrointestinal Toxicity, Neutropenia, Infection

Drug(s) suspected as cause:
Carboplatin
    Dosage: 6 courses in high risk
    Indication: Retinoblastoma

Cyclophosphamide
    Indication: Retinoblastoma

Doxorubicin HCL
    Dosage: 4 courses in intermediate risk and 6 courses in high risk
    Indication: Retinoblastoma

Etoposide
    Indication: Retinoblastoma

Vincristine
    Dosage: 4 courses in intermediate risk and 6 courses in high risk
    Indication: Retinoblastoma

Other drugs received by patient: Neupogen



Possible Cyclophosphamide side effects in

Reported by a individual with unspecified qualification from United States on 2012-08-21

Patient: , weighing 61.4 kg (135.1 pounds)

Reactions: Neutropenia, Enterocolitis

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Carboplatin
    Dosage: 2150 mg
    Start date: 2012-07-13

Cyclophosphamide
    Dosage: 1000 mg
    Start date: 2012-08-09

Doxorubicin Hydrochloride
    Dosage: 100 mg
    Start date: 2012-08-09

Taxol
    Dosage: 1242 mg
    Start date: 2012-08-03



Possible Cyclophosphamide side effects in male

Reported by a health professional (non-physician/pharmacist) from France on 2012-08-20

Patient: male

Reactions: Neutropenia, Infection

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Start date: 2012-05-21
    End date: 2012-05-21

Cyclophosphamide
    Start date: 2012-07-02
    End date: 2012-07-02

Cyclophosphamide
    Start date: 2012-07-23
    End date: 2012-07-23

Cyclophosphamide
    Start date: 2012-06-11
    End date: 2012-06-11

Doxorubicin Hydrochloride
    Start date: 2012-05-21
    End date: 2012-05-21

Doxorubicin Hydrochloride
    Start date: 2012-06-11
    End date: 2012-06-11

Doxorubicin Hydrochloride
    Start date: 2012-07-23
    End date: 2012-07-23

Doxorubicin Hydrochloride
    Start date: 2012-07-02
    End date: 2012-07-02

Etopophos Preservative Free
    Start date: 2012-06-11
    End date: 2012-06-11

Etopophos Preservative Free
    Start date: 2012-07-02
    End date: 2012-07-02

Etopophos Preservative Free
    Start date: 2012-07-23
    End date: 2012-07-23

Etopophos Preservative Free
    Start date: 2012-05-21
    End date: 2012-05-21

Mabthera
    Start date: 2012-05-21
    End date: 2012-05-21

Mabthera
    Start date: 2012-07-02
    End date: 2012-07-02

Mabthera
    Start date: 2012-06-11
    End date: 2012-06-11

Mabthera
    Start date: 2012-07-23
    End date: 2012-07-23

Other drugs received by patient: Acetaminophen; Lovenox; Nexium; Crestor; Clopidogrel Bisulfate and Aspirin; Valacyclovir Hydrochloride; Acebutolol



Possible Cyclophosphamide side effects in

Reported by a health professional (non-physician/pharmacist) from Italy on 2012-08-20

Patient:

Reactions: Abdominal Pain, Vomiting, Hypersensitivity, Nausea, Skin Toxicity, Mucosal Inflammation, Fatigue, Diarrhoea, Hepatotoxicity, Neutropenia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: Breast Cancer

Epirubicin
    Indication: Breast Cancer

Fluorouracil
    Indication: Breast Cancer

Herceptin
    Dosage: loading dose
    Indication: Breast Cancer

Herceptin
    Dosage: maintenance dose

Lapatinib
    Dosage: arm b
    Administration route: Oral
    Indication: Breast Cancer

Lapatinib
    Dosage: arm c
    Administration route: Oral

Paclitaxel
    Indication: Breast Cancer



Possible Cyclophosphamide side effects in 55 year old female

Reported by a health professional (non-physician/pharmacist) from Japan on 2012-08-18

Patient: 55 year old female

Reactions: Malaise, Neutropenia, Wound Infection

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: Breast Cancer

Dexamethasone
    Dosage: 8 mg

Dexamethasone
    Dosage: 8 mg
    Administration route: Oral
    Indication: Supportive Care

Docetaxel
    Indication: Breast Cancer



Possible Cyclophosphamide side effects in female

Reported by a physician from United States on 2012-08-16

Patient: female

Reactions: Abdominal Pain, Vomiting, Nausea, Palmar-Plantar Erythrodysaesthesia Syndrome, Febrile Neutropenia, Peripheral Sensory Neuropathy, Constipation, Fatigue, Diarrhoea, Neutropenia

Drug(s) suspected as cause:
Adriamycin PFS
    Dosage: cycle 3

Adriamycin PFS
    Dosage: cycle 4

Adriamycin PFS
    Dosage: cycle 2

Adriamycin PFS
    Dosage: cycle 1
    Indication: Breast Cancer

Cyclophosphamide
    Dosage: cycle 4

Cyclophosphamide
    Dosage: cycle 3
    Indication: Breast Cancer

Cyclophosphamide
    Dosage: cycle 1

Cyclophosphamide
    Dosage: cycle 2

Docetaxel
    Dosage: cycle 4

Docetaxel
    Dosage: cycle 3
    Indication: Breast Cancer

Docetaxel
    Dosage: cycle 2

Docetaxel
    Dosage: cycle 1

Doxorubicin Hydrochloride
    Dosage: cycle 3

Doxorubicin Hydrochloride
    Dosage: cycle 4
    Indication: Breast Cancer

Doxorubicin Hydrochloride
    Dosage: cycle 1

Doxorubicin Hydrochloride
    Dosage: cycle 2

NOV-002

NOV-002
    Dosage: administered approximately 3 hr apart
    Indication: Breast Cancer

NOV-002



Possible Cyclophosphamide side effects in

Reported by a physician from United States on 2012-08-16

Patient:

Reactions: Nausea, Pain, Motor Dysfunction, Rash, Peripheral Sensory Neuropathy, Fatigue, Blood Potassium Decreased, Dyspepsia, Diarrhoea, Neutropenia, Thrombocytopenia

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: on day 1

Cyclophosphamide
    Dosage: on day 1
    Indication: Lymphocytic Lymphoma

Cyclophosphamide
    Dosage: on day 1
    Indication: non-Hodgkin's Lymphoma

Cyclophosphamide
    Dosage: on day 1
    Indication: B-Cell Lymphoma

Cyclophosphamide
    Dosage: on day 1
    Indication: Lymphoma

Cyclophosphamide
    Dosage: on day 1
    Indication: Waldenstrom's Macroglobulinaemia

Doxorubicin HCL
    Dosage: on day 1
    Indication: non-Hodgkin's Lymphoma

Doxorubicin HCL
    Dosage: on day 1

Doxorubicin HCL
    Dosage: on day 1

Doxorubicin HCL
    Dosage: on day 1
    Indication: Lymphoma

Doxorubicin HCL
    Dosage: on day 1

Doxorubicin HCL
    Dosage: on day 1
    Indication: Waldenstrom's Macroglobulinaemia

Doxorubicin HCL
    Dosage: on day 1
    Indication: B-Cell Lymphoma

Doxorubicin HCL
    Dosage: on day 1

Doxorubicin HCL
    Dosage: on day 1
    Indication: Lymphocytic Lymphoma

Doxorubicin HCL
    Dosage: on day 1

Doxorubicin HCL
    Dosage: on day 1

Doxorubicin HCL
    Dosage: on day 1

Prednisone TAB
    Dosage: on days 1-5
    Administration route: Oral
    Indication: B-Cell Lymphoma

Prednisone TAB
    Dosage: on days 1-5
    Administration route: Oral
    Indication: Waldenstrom's Macroglobulinaemia

Prednisone TAB
    Dosage: on days 1-5
    Administration route: Oral
    Indication: non-Hodgkin's Lymphoma

Prednisone TAB
    Dosage: on days 1-5
    Administration route: Oral

Prednisone TAB
    Dosage: on days 1-5
    Administration route: Oral
    Indication: Lymphoma

Prednisone TAB
    Dosage: on days 1-5
    Administration route: Oral
    Indication: Lymphocytic Lymphoma

Rituximab
    Dosage: on day 1
    Indication: Waldenstrom's Macroglobulinaemia

Rituximab
    Dosage: on day 1

Rituximab
    Dosage: maintenance

Rituximab
    Dosage: on day 1

Rituximab
    Dosage: maintenance
    Indication: Lymphocytic Lymphoma

Rituximab
    Dosage: maintenance
    Indication: B-Cell Lymphoma

Rituximab
    Dosage: on day 1

Rituximab
    Dosage: maintenance
    Indication: non-Hodgkin's Lymphoma

Rituximab
    Dosage: on day 1

Rituximab
    Dosage: maintenance

Rituximab
    Dosage: maintenance
    Indication: Lymphoma

Rituximab
    Dosage: on day 1

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
    Indication: B-Cell Lymphoma

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
    Indication: Lymphoma

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
    Indication: Waldenstrom's Macroglobulinaemia

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
    Indication: Lymphocytic Lymphoma

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
    Indication: non-Hodgkin's Lymphoma

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: non-Hodgkin's Lymphoma

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: Waldenstrom's Macroglobulinaemia

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: Lymphoma

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: B-Cell Lymphoma

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: Lymphocytic Lymphoma

Other drugs received by patient: Acetaminophen; Diphenhydramine Hydrochloride; Ondansetron



Possible Cyclophosphamide side effects in female

Reported by a health professional (non-physician/pharmacist) from Norway on 2012-08-16

Patient: female

Reactions: Colitis, Neutropenia

Drug(s) suspected as cause:
Azathioprine Sodium
    Indication: Wegener's Granulomatosis

Cellcept
    Indication: Wegener's Granulomatosis

Cyclophosphamide
    Indication: Wegener's Granulomatosis

Everolimus
    Indication: Wegener's Granulomatosis

Immune Globulin NOS
    Indication: Wegener's Granulomatosis

Mabthera
    Dosage: given after 1 month from the event
    Indication: Wegener's Granulomatosis
    Start date: 2006-11-01

Mabthera
    Indication: Rheumatoid Arthritis
    Start date: 2006-11-01

Methotrexate
    Indication: Wegener's Granulomatosis

Methotrexate
    Indication: Off Label Use

Tacrolimus
    Indication: Wegener's Granulomatosis

Other drugs received by patient: Prednisolone



Possible Cyclophosphamide side effects in male

Reported by a health professional (non-physician/pharmacist) from Norway on 2012-08-15

Patient: male

Reactions: Neutropenia

Drug(s) suspected as cause:
Azathioprine Sodium
    Indication: Wegener's Granulomatosis

Cyclophosphamide
    Indication: Wegener's Granulomatosis

Cyclophosphamide
    Indication: Pancytopenia

Immune Globulin Intravenous (Human)
    Indication: Wegener's Granulomatosis

Immune Globulin Intravenous (Human)
    Indication: Hypogammaglobulinaemia

Mabthera
    Indication: Rheumatoid Arthritis
    Start date: 2007-03-01

Mabthera
    Dosage: given after 2 months from the event
    Indication: Wegener's Granulomatosis

Methotrexate
    Indication: Truss User

Methotrexate
    Indication: Wegener's Granulomatosis

Other drugs received by patient: Prednisolone



Possible Cyclophosphamide side effects in 64 year old male

Reported by a health professional (non-physician/pharmacist) from Italy on 2012-08-08

Patient: 64 year old male

Reactions: Pneumonia, Neutropenia, Leukaemia Plasmacytic, Disease Progression

Adverse event resulted in: death

Drug(s) suspected as cause:
Bortezomib
    Indication: Leukaemia Plasmacytic

Cyclophosphamide
    Dosage: 1 g
    Indication: Leukaemia Plasmacytic

Dexamethasone
    Dosage: 40 mg

Dexamethasone
    Dosage: 40 mg
    Indication: Leukaemia Plasmacytic

Lenalidomide
    Dosage: 25 mg
    Indication: Leukaemia Plasmacytic



Possible Cyclophosphamide side effects in

Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-07

Patient:

Reactions: Hospitalisation, Neuropathy Peripheral, Vomiting, Febrile Neutropenia, Neutropenia, Neutrophil Count Decreased, Lymphoma

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: B-Cell Lymphoma

Cyclophosphamide
    Indication: Diffuse Large B-Cell Lymphoma

Doxorubicin Hydrochloride
    Indication: B-Cell Lymphoma

Doxorubicin Hydrochloride
    Indication: Diffuse Large B-Cell Lymphoma

Prednisone
    Dosage: for 5 days
    Indication: B-Cell Lymphoma

Prednisone
    Dosage: for 5 days
    Indication: Diffuse Large B-Cell Lymphoma

Radiotherapy
    Indication: Diffuse Large B-Cell Lymphoma

Radiotherapy
    Indication: B-Cell Lymphoma

Rituximab
    Indication: B-Cell Lymphoma

Rituximab
    Indication: Diffuse Large B-Cell Lymphoma

Vincristine
    Indication: B-Cell Lymphoma

Vincristine
    Indication: Diffuse Large B-Cell Lymphoma

Other drugs received by patient: Neupogen



Possible Cyclophosphamide side effects in

Reported by a physician from Spain on 2012-08-06

Patient:

Reactions: Skin Toxicity, Sudden Death, Hepatic Failure, Encephalitis, Cytomegalovirus Colitis, Pneumonia Pneumococcal, Neurotoxicity, Death, Multi-Organ Failure, Metastasis, Cardiotoxicity, AIDS Dementia Complex, Pseudomonas Infection, Toxicity To Various Agents, Staphylococcal Infection, Pneumonia Herpes Viral, Neutropenia, Escherichia Infection, Infection

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: given on day 1 of the 3 week cycle
    Indication: Lymphoma AIDS Related

Doxorubicin HCL
    Dosage: given on day 1 of the 3 week cycle
    Indication: Lymphoma AIDS Related

Mabthera
    Dosage: given on day 1 of every 3 week cycle (prior to chop)
    Indication: Lymphoma AIDS Related

Prednisone TAB
    Dosage: given for 5 days
    Administration route: Oral
    Indication: Lymphoma AIDS Related

Vincristine Sulfate
    Dosage: given on day 1 of 3 week cycle.
    Indication: Lymphoma AIDS Related

Other drugs received by patient: Hydrocortisone; Cytarabine; Methotrexate



Possible Cyclophosphamide side effects in 76 year old

Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-02

Patient: 76 year old

Reactions: Lung Disorder, Neutropenia, Infection

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: Diffuse Large B-Cell Lymphoma

Doxorubicin Hydrochloride
    Indication: Diffuse Large B-Cell Lymphoma

Prednisone
    Dosage: daily for 5 days
    Indication: Diffuse Large B-Cell Lymphoma

Radiotherapy
    Indication: Diffuse Large B-Cell Lymphoma

Rituximab
    Indication: Diffuse Large B-Cell Lymphoma

Vincristine
    Indication: Diffuse Large B-Cell Lymphoma

Other drugs received by patient: Neupogen



Possible Cyclophosphamide side effects in 58 year old male

Reported by a health professional (non-physician/pharmacist) on 2012-08-02

Patient: 58 year old male, weighing 77.0 kg (169.4 pounds)

Reactions: Haemoglobin Decreased, White Blood Cell Count Decreased, Platelet Count Decreased, Neutropenia

Drug(s) suspected as cause:
Asparaginase (Unspecified) (Asparginase) (Unknown)
    Indication: Chemotherapy
    Start date: 2012-03-12

Cyclophosphamide
    Indication: Chemotherapy
    Start date: 2012-03-12

Dexamethasone
    Indication: Chemotherapy
    Start date: 2012-03-12

Doxorubicin HCL
    Indication: Chemotherapy
    Start date: 2012-03-12

Isavuconazole (Isavuconazole)
    Dosage: three times daily, intravenous (not otherwise specified)
    Indication: Fungal Infection
    Start date: 2012-02-07
    End date: 2012-02-09

Vincristine
    Indication: Chemotherapy
    Start date: 2012-03-12

Other drugs received by patient: Metronidazole; Ciprofloxacin



Possible Cyclophosphamide side effects in

Reported by a physician from United States on 2012-08-01

Patient:

Reactions: Nausea, Motor Dysfunction, Pain, Rash, Peripheral Sensory Neuropathy, Fatigue, Dyspepsia, Blood Potassium Decreased, Diarrhoea, Neutropenia, Thrombocytopenia

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: on day 1
    Indication: Waldenstrom's Macroglobulinaemia

Cyclophosphamide
    Dosage: on day 1
    Indication: B-Cell Lymphoma

Cyclophosphamide
    Dosage: on day 1
    Indication: Lymphoma

Cyclophosphamide
    Dosage: on day 1
    Indication: non-Hodgkin's Lymphoma

Cyclophosphamide
    Dosage: on day 1
    Indication: Lymphocytic Lymphoma

Cyclophosphamide
    Dosage: on day 1

Doxorubicin Hydrochloride
    Dosage: on day 1
    Indication: Waldenstrom's Macroglobulinaemia

Doxorubicin Hydrochloride
    Dosage: on day 1
    Indication: Lymphoma

Doxorubicin Hydrochloride
    Dosage: on day 1
    Indication: non-Hodgkin's Lymphoma

Doxorubicin Hydrochloride
    Dosage: on day 1
    Indication: Lymphocytic Lymphoma

Doxorubicin Hydrochloride
    Dosage: on day 1

Doxorubicin Hydrochloride
    Dosage: on day 1
    Indication: B-Cell Lymphoma

Prednisone
    Dosage: on days 1-5
    Administration route: Oral
    Indication: Lymphoma

Prednisone
    Dosage: on days 1-5
    Administration route: Oral
    Indication: B-Cell Lymphoma

Prednisone
    Dosage: on days 1-5
    Administration route: Oral
    Indication: Waldenstrom's Macroglobulinaemia

Prednisone
    Dosage: on days 1-5
    Administration route: Oral
    Indication: Lymphocytic Lymphoma

Prednisone
    Dosage: on days 1-5
    Administration route: Oral

Prednisone
    Dosage: on days 1-5
    Administration route: Oral
    Indication: non-Hodgkin's Lymphoma

Rituximab
    Dosage: maintenance
    Indication: Waldenstrom's Macroglobulinaemia

Rituximab
    Dosage: maintenance

Rituximab
    Dosage: on day 1
    Indication: Lymphocytic Lymphoma

Rituximab
    Dosage: maintenance

Rituximab
    Dosage: on day 1

Rituximab
    Dosage: on day 1
    Indication: B-Cell Lymphoma

Rituximab
    Dosage: on day 1
    Indication: non-Hodgkin's Lymphoma

Rituximab
    Dosage: maintenance

Rituximab
    Dosage: maintenance

Rituximab
    Dosage: on day 1
    Indication: Lymphoma

Rituximab
    Dosage: maintenance

Rituximab
    Dosage: on day 1

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
    Indication: non-Hodgkin's Lymphoma

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
    Indication: B-Cell Lymphoma

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
    Indication: Lymphoma

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
    Indication: Lymphocytic Lymphoma

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
    Indication: Waldenstrom's Macroglobulinaemia

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: Waldenstrom's Macroglobulinaemia

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: Lymphocytic Lymphoma

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: B-Cell Lymphoma

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: non-Hodgkin's Lymphoma

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: Lymphoma

Other drugs received by patient: Diphenhydramine HCL; Acetaminophen; Ondansetron



Possible Cyclophosphamide side effects in

Reported by a physician from United Kingdom on 2012-08-01

Patient:

Reactions: Neutropenia, Infection

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 1440 mg, unk
    Indication: Mantle Cell Lymphoma

Doxorubicin Hydrochloride
    Dosage: 96 mg, unk
    Indication: Mantle Cell Lymphoma

Prednisone
    Dosage: 100 mg, unk
    Indication: Mantle Cell Lymphoma

Prednisone
    Dosage: 80 unk, unk

Velcade
    Dosage: 3 mg, unk
    Indication: Mantle Cell Lymphoma
    Start date: 2011-01-27

Vincristine
    Indication: Mantle Cell Lymphoma

Other drugs received by patient: Sando K / 00031402 /



Possible Cyclophosphamide side effects in male

Reported by a health professional (non-physician/pharmacist) from United Kingdom on 2012-08-01

Patient: male

Reactions: Neutropenia

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: B-Cell Lymphoma

Doxorubicin Hydrochloride
    Indication: B-Cell Lymphoma

Mabthera
    Indication: B-Cell Lymphoma

Prednisone
    Indication: B-Cell Lymphoma

Vincristine
    Indication: B-Cell Lymphoma



Possible Cyclophosphamide side effects in

Reported by a health professional (non-physician/pharmacist) from Russian Federation on 2012-07-31

Patient:

Reactions: Vomiting, Acute Leukaemia, Febrile Neutropenia, Treatment Failure, Neutropenia, Toxicity To Various Agents, Neoplasm, Leukopenia

Adverse event resulted in: death

Drug(s) suspected as cause:
Bleomycin Sulfate
    Dosage: as part of abvd or beacopp
    Indication: Hodgkin's Disease

Chemoradiation
    Indication: Hodgkin's Disease

Cyclophosphamide
    Indication: Hodgkin's Disease

Dacarbazine
    Indication: Hodgkin's Disease

Doxorubicin Hydrochloride
    Dosage: as part of abvd or beacopp
    Indication: Hodgkin's Disease

Etoposide
    Indication: Hodgkin's Disease

Prednisone
    Indication: Hodgkin's Disease

Procarbazine Hydrochloride
    Indication: Hodgkin's Disease

Vinblastine Sulfate
    Indication: Hodgkin's Disease

Vincristine
    Indication: Hodgkin's Disease



Possible Cyclophosphamide side effects in 70 year old female

Reported by a health professional (non-physician/pharmacist) from United Kingdom on 2012-07-30

Patient: 70 year old female

Reactions: Renal Impairment, Hyperkalaemia, Anaemia, Neutropenia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Administration route: Oral
    Indication: Multiple Myeloma
    Start date: 2010-09-24
    End date: 2010-11-03

Dexamethasone
    Indication: Multiple Myeloma
    Start date: 2010-09-24
    End date: 2010-11-03

Revlimid
    Dosage: 10 milligram
    Administration route: Oral
    Indication: Multiple Myeloma
    Start date: 2010-09-24
    End date: 2010-11-03



Possible Cyclophosphamide side effects in male

Reported by a health professional (non-physician/pharmacist) from United Kingdom on 2012-07-27

Patient: male

Reactions: Neutropenia, Haematotoxicity

Drug(s) suspected as cause:
(Mabthera)
    Indication: B-Cell Lymphoma

Cyclophosphamide
    Indication: B-Cell Lymphoma

Doxorubicin Hydrochloride
    Indication: B-Cell Lymphoma

Prednisone TAB
    Indication: B-Cell Lymphoma

Vincristine Sulfate
    Indication: B-Cell Lymphoma



Possible Cyclophosphamide side effects in female

Reported by a health professional (non-physician/pharmacist) from Germany on 2012-07-27

Patient: female, weighing 67.7 kg (148.9 pounds)

Reactions: Febrile Neutropenia, Neutropenia, Bronchitis, Thrombocytopenia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Start date: 2012-05-24

Cyclophosphamide
    Start date: 2012-04-12

Epirubicin Hydrochloride
    Start date: 2012-05-24

Epirubicin Hydrochloride
    Start date: 2012-04-12

Fluorouracil
    Start date: 2012-04-12

Fluorouracil
    Start date: 2012-05-24

Other drugs received by patient: Nobiten; Pantoprazole; Simvastatine EG; Escitalopram Oxalate



 Page 1   Next >>

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014